Treatment of upper aerodigestive tract cancers in England and its effect on survival by Edwards, Dympna M & Johnson, N W
Despite advances in treatment, survival from upper aerodigestive
tract cancers has not changed significantly on a population basis in
Europe over the past 40 years (Berrino et al, 1995). In this study,
upper aerodigestive tract (UAT) cancers refer to malignant
neoplasms of the mouth, pharynx, larynx and associated structures
(ICD10: C00–C14, C30–C32). They are mainly, but not exclu-
sively, squamous cell carcinomas. Cancers of the thyroid, maxilla
and mandible are excluded. UAT cancers are a significant and
growing public health problem (MacFarlane et al, 1992). They are
the third most common cancer in males world-wide and the
seventh most common in females comprising 10.1% and 4.4% of
cancer cases respectively (Parkin et al, 1993).
There is little population-based treatment information on UAT
cancers available in the UK. Although a few individuals have
developed audit databases (Woolgar, 1995; Worrall, 1995), in a
1996 survey of consultants treating head and neck cancers in the
UK, only 4% of consultants reported using any standardized
method of recording clinical information (Edwards et al, 1997).
Over the past 50 years regional cancer registries in the UK have
collected population-based information on cancers. They have
limited treatment details, although there are differences in the type
of information collected by each registry.
The major treatments for UAT cancers are surgery, radiotherapy
and, to a lesser extent, chemotherapy. Surgical advances include
the use of microvascular techniques, the radial forearm free flap
(Soutar and McGregor, 1986; Vaughan et al, 1992; Vaughan and
Brown, 1994) and percutaneous gastric feeding. The evidence
base for treatments is low with most treatments being based on
case series. Of the approximate 65 000 patients diagnosed with
UAT cancers from 1984 to 1993 only 2273 (3.5%) patients were
enrolled in randomized controlled trials of treatment registered
with the United Kingdom Coordinating Committee on Cancer
Research (UKCCCR, personal communication). Some analytical
studies which compare the outcomes of different surgical treat-
ments have been published, but these are generally non-random-
ized, retrospective observational studies with low numbers
(Mendenhall et al, 1988; Weber et al, 1990; Davidson et al, 1991;
Mitchell and Crighton, 1993; Fein et al, 1994; Nisi et al, 1998).
Radiotherapy fractionation protocols used in the UK have
varied widely and been determined more by the equipment avail-
able than by evidence of effectiveness (Priestman et al, 1989).
There has been a move towards combined surgical and radio-
therapy treatment for advanced UAT cancers (Mendenhall et al,
1988; Glaholm, 1998; Nisi et al, 1998). Compared with single
modality treatment combined surgery and radiotherapy has been
found to improve outcomes for advanced tongue (Weber et al,
1990), pharyngeal (Bentzen et al, 1991) and laryngeal cancers
(Vermund et al, 1990). Radiotherapy is routinely given post-opera-
tively as it is associated with a lower recurrence rate than preoper-
atively (Tupchong, 1991). There is evidence from a number of
studies that interruption in radiotherapy treatment and extension of
treatment beyond 30 days because of interruptions reduce control
rates for cancers of the oropharynx and larynx (Amdur et al, 1989;
Slaladowski et al, 1994; Duncan et al, 1996; Wang et al, 1996).
There is some controversy about which treatments are appro-
priate for which cancers. Several studies have shown better
functional and quality of life outcomes for patients treated with
radiotherapy than for those treated with surgery for base of tongue
cancers (Harrison et al, 1994; Moore et al, 1996; Zelefsky et al,
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© 1999 Cancer Research Campaign1996), buccopharyngeal cancers (Morton et al, 1984; Morton,
1997) and laryngeal cancers (Stewart et al, 1998), but others show
better results for surgery (Fein et al, 1994). Although combined
therapy may increase local control Rathmell et al (1991) found
that patients with advanced UAT cancers treated with both surgery
and radiotherapy had worse quality of life than those treated with
radiotherapy alone.
There is anecdotal evidence of differences in treatment
protocols between centres. Because of this a number of treatment
guidelines have been developed. The British Association of
Orolaryngologists–Head and Neck Surgeons have recently
produced an extensive set of guidelines (1998). Treatment guide-
lines were considered by the British Association of Head and Neck
Oncologists in an early draft of their publication on standards for
head and neck cancer care (1998) and the British Association of
Surgical Oncologists are in the process of producing guidelines for
treatment. Surgical protocols have been developed by the German,
Swiss and Austrian group DOSAK (Platz et al, 1986), there are
joint guidelines by the American Society for Head and Neck
Surgery and the Society of Head and Neck Surgeons (1996) and in
a forthcoming publication Glaholm (1999) suggests recommended
treatment for oral cancers. There is some agreement between the
guidelines on recommended treatments. Table 1 outlines the
common recommendations in the above guidelines. Recom-
mendations usually focus on single modality treatment in small
tumours and combined treatment in larger tumours. They recom-
mend that radiotherapy be given within one month of surgery and
delays in radiotherapy be avoided (Glaholm, 1999).
The Scottish Intercollegiate Guidelines Network (SIGN) grades
the evidence on which guidelines are based from 1 to 4 (Grimshaw
and Russell, 1993), 1 being the most reliable and 4 the least
reliable. Most of the guidelines above on UAT treatment relating
to surgery and radiotherapy treatment are based on level 3 and 4
evidence. The detail of the recommendations differs between
sources and some of the guidelines are so general as to allow
several forms of treatment. For example, most guidelines recom-
mend neck dissection for lymph nodes that are clinically negative
but where there is a high probability of lymph node metastases.
How the probability of metastases is determined and the type of
neck dissection recommended vary in the guidelines, some of
which also recommend radiotherapy as an alternative or adjunct to
neck dissection.
The aims of the study were to describe current patterns of treat-
ment in three large areas of the UK, to investigate whether and
how the treatment varies from guidelines and to investigate the
influence of treatment on survival for UAT cancers.
METHODS
This was a retrospective population-based multi-regional observa-
tional study. The Thames, West Midlands and Yorkshire cancer
registries provided data on all malignant cases of UAT cancers
(C00–C14, C30–C32) diagnosed and registered in their regions
from 1984 to 1993. This comprised 18 795 cases, 44% of all cases
of UAT cancers in England and Wales over his 10-year period
(Office for National Statistics, cancer registration data). The
regions have been anonymized at the request of the cancer
registries.
Demographic information was available on patients’ age at
diagnosis, gender, deprivation, ethnic and marital status. We allo-
cated a Carstairs deprivation score to each person based on their
enumeration district of residence, linked through their postcode
(Dolk et al, 1995). This is a well recognized measure of material
deprivation and has been used in previous studies of UAT cancers
(Thorne, 1997). Details of the tumour site, histological grade and
extent of spread was available. TNM stage was available for only
a minority of cases, however, a cancer registry extent of spread
classification was available for regions 1 and 2. This classified
tumours as within their organ of origin (level 1), having local
spread (level 2), having nodal spread (level 3) and having distant
metastases (level 4). Death was the only outcome measure
available. The date and sequence of surgery, radiotherapy and
chemotherapy was available for each case, but not details of the
procedures, techniques or drugs used.
Six per cent of cases had information from death certificates
only, ranging from 0.5% to 11% by region and another 6% of
patients had had no active treatment. Treatment information was
available for 13 510 patients being 77% complete. Treatment
information was collected for the first 6 months following
diagnosis in regions 1 and 2 and most treatments for the first
9 weeks following diagnosis in region 3.
We analysed crude survival (from all causes of death) from the
date of diagnosis to the date of death or until 31 December 1995
for regions 1 and 2. Extent of spread and grade were not available
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Table 1 Recommended protocols and adherence to protocols
Site Recommended treatments % Receiving Recommended treatments % Receiving
recommended recommended
treatment treatment
T1/T2 Extent of spread 1 T3/T4 Extent of spread 2–4
Lip Surgery or radiotherapy 82 Surgery and radiotherapy 72
Mouth Surgery or radiotherapy 71 Surgery and radiotherapy 35
Oropharynx Radiotherapy 52 Surgery and radiotherapy 31
Nasopharynx Radiotherapy 75 Radiotherapy or surgery and radiotherapy 96
Larynx Radiotherapy or surgery and radiotherapy 71 Surgery and radiotherapy 77
Salivary glands Surgery 38 Surgery or surgery and radiotherapy 81
Total 67 57for region 3, so these cases were excluded from the survival
analysis. Although the Office for National Statistics had not
informed cancer registries of non-cancer deaths from 1992
onwards analysis of survival at different time periods showed that
this did not affect the results. We used the SPSS package for
analysis with a chi-squared test to assess differences in treatment.
We used forward step-wise Cox proportional hazard model with a
likelihood ratio test in the multivariate analyses. We undertook
this for each site group, mouth (C01–C06), larynx (C32) and
pharynx (C09, C10, C12–C14) entering the variables in the order:
extent of spread, site (for mouth and pharynx, tumour grade, age,
deprivation, marital status and treatment. All other sites were
excluded from the survival analysis.
RESULTS
The 12 972 patients had a total of 21 197 treatments with some
patients having multiple treatments and some recurrences. Patients
in region 1 were more affluent than in other regions. Region 2 had
a different site distribution than other regions. This was due to
incompleteness of treatment data for laryngeal cancers in this
region (Table 2). There were no regional differences in incidence.
The main treatments were radiotherapy and surgery. There were no
major trends in treatment over time in any of the regions. Men with
oral cancer were slightly more likely to have radiotherapy alone
than women (46% compared with 40% P < 0.001) and women
with oral cancer were more likely to receive surgery alone than
men (30% compared with 23%, P < 0.001). There were no major
gender differences in treatment of cancer of the larynx or pharynx.
There were some age-related differences in treatment, when site
was taken into account. People over the age of 75 years at diag-
nosis were more likely to have had radiotherapy alone at all sites
and less likely to have had surgery and radiotherapy in sequence
(more than three months apart, P < 0.001, Table 3). Seven per cent
of over 75-year-olds had no treatment compared with 2.5% of
those less than 75 years of age (P < 0.001).
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Table 2 Demographic and tumour characteristics of patients receiving treatment by region
Number/% of patients Region 1 Region 2 Region 3
Number % Number % Number %
Age at diagnosis <60 years 2127 30.7 1072 33.6 1063 31.4
60–74 years 3158 45.6 1483 46.5 1639 48.3
75+ years 1641 23.7 637 20.0 688 20.3
Gender Male 4786 69.1 2201 68.9 2380 70.2
UK Carstairs quintile
Quintile 1 1609 23.2 520 16.3 545 16.1
Quintile 2–3 3033 43.8 1134 35.5 1405 41.4
Quintile 4–5 2284 33.0 1540 48.2 1440 42.5
Site distribution
Mouth cancers C01–C06 1792 25.9 1267 39.7 988 29.1
Larynx C32 2456 35.5 795 24.9 1263 37.3
Pharynx excluding 21712 24.7 697 21.8 687 20.3
nasopharynx C09,C10,C12–C14
Others 1517 13.9 690 10.7 566 13.5
Registry Stage distribution
Stage 1 (confined to organ of 3011 47.1 1166 51.6 Data missing
origin)
Levels 2–4 3383 52.9 1095 48.4 Data missing
Table 3 Treatment by site and age at diagnosis
75+ years 60–74 years <60 years Total
Number % Number % Number % Number %
Mouth C01–C06 Radiotherapy 544 51.3 841 42.7 581 38.1 1966 43.2
Surgery 275 25.9 502 25.5 388 25.4 1165 25.6
Combined S&R* 127 12.0 329 16.7 281 18.4 737 16.2
S&R* sequence 114 10.8 298 15.1 276 18.1 688 15.1
Total 1060 100 1970 100 1526 100 4556 100
Pharynx C09, C10, C12–C14 Radiotherapy 483 64.0 870 56.5 558 49.3 1911 55.8
Surgery 111 14.7 176 11.4 150 13.3 437 12.8
Combined S&R 120 15.9 317 20.6 243 21.5 680 19.8
S&R sequence 41 5.4 176 11.4 181 16.0 398 11.6
Total 755 100 1539 100 1132 100 3426 100
Larynx C32 Radiotherapy 714 73.1 1822 67.0 860 66.6 3396 68.1
Surgery 91 9.3 260 9.6 112 8.7 463 9.3
Combined S&R 121 12.4 405 14.9 198 15.3 724 14.5
S&R sequence 51 5.2 234 8.6 122 9.4 407 8.2
Total 977 100 2721 100 1292 100 4990 100
S = surgery; R = radiotherapy.The recommended treatments outlined in Table 1 were adhered
to in 60% of all treatments. Those guidelines that allowed for
several forms of treatment had higher adherence as would be
expected (Table 1). Cancer registry levels 2–4 are broadly equiva-
lent to T3 or T4 stages in that a tumour greater than 4 cm in the
upper aerodigestive tract (T3 or above) is likely to invade adjacent
structures (level 2 or above) (Howells, 1995). Cancer registry level
1 is equivalent to T1 and T2. Some patients at cancer registry level
1 had combination therapy accounting for the low adherence to
guidelines. Only 38% of patients with salivary gland cancers had
the recommended treatment of surgery alone for extent of spread 1
tumours, whereas 85% had surgery either alone or in combination
with radiotherapy. Similarly, only 35% of patients had the recom-
mended treatment of both surgery and radiotherapy for level 2–4
oral cancers; 42% had radiotherapy alone and another 23%
surgery alone. In this analysis the timing and order of treatment
was not taken into account. If it had been, the adherence to guide-
lines may have been lower.
Thirty per cent of all patients had both surgery and radiotherapy;
32% of patients in region 1, 29% in region 2 and 16% in region 3,
treatment details being recorded for the first 26 weeks in regions 1
and 2 and for the first 9 weeks in region 3 (Table 4). There was a
trend towards dual treatment with 20% of patients treated in
1984–1986 having both surgery and radiotherapy compared
with 29% in 1987–1990 and 30% in 1991–1993 (P < 0.001).
Preoperative radiotherapy comprised 7.5% of combined treatment
and this did not vary much by site or time. Fewer than half of the
patients treated with combined surgery and radiotherapy (within
3 months) had the treatments less than 1 month apart, as currently
recommended (Glaholm 1998), ranging from 25% for region 2
to 45% for region 3. A greater proportion of patients treated with
both surgery and radiotherapy had their treatments within 3
months of each other over time (68% in 1984–1986, 76% in
1987–1990 and 84% in 1991–1993 P < 0.001) but there was no
increase in the proportion of patients who had the treatments
within 1 month of each other.
Oral cancer patients who were treated by surgery had better
survival than those treated with radiotherapy, or both surgery and
radiotherapy. Oral cancer patients treated with surgery alone had
half the risk of death (relative risk (RR) 0.46, 0.39–0.53), and
those with combined treatment two-thirds the risk of death (RR
0.64, 0.55–0.74) of those who had radiotherapy alone (Table 5).
These differences occurred independent of tumour and demo-
graphic prognostic factors. Although either radiotherapy or
surgery alone was recommended in the guidelines for small mouth
cancers (T1/T2, Table 1), oral cancers confined to their organ of
origin treated by surgery had significantly better survival than
radiotherapy (Figure 1).
Radiotherapy was associated with better survival for cancer of
the larynx compared with surgery or surgery and radiotherapy in
sequence independent of tumour or demographic factors (Table 5).
Combined treatment was independently associated with the best
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Table 4 Timing and order of treatments for people who had both radiotherapy and surgery
Number (%) Region 1 Region 2 Region 3
1984–1992 1984–1993 1984–1993
Number % Number % Number %
Total number of patients having both surgery and radiotherapy 7485 50.0 1481 23 435 15.7
Treatments in sequence (more than 3 months between treatments)
Surgery followed by radiotherapy 1222 16.3 440 32.7 95 15.0
Radiotherapy followed by surgery 1108 14.8 355 26.4 59 9.0
Combined treatment (within 3 months) 5155 68.9 552 41.0 496 76.0
Surgery first 4361 84.6 477 86.4 435 87.7
Radiotherapy first 403 7.8 59 10.7 7 1.4
Within 1 week 391 7.6 16 2.9 54 10.9
Combined treatments within 1 month 2122 40.9 143 25.9 131 45.4
Combined treatment 1–3 months apart 3043 59.1 409 74.1 157 54.6
Table 5 Multivariate analysis of crude survival by treatment. Site, stage, grade, age, deprivation and marital status in Cox’s proportional hazard model.
Site Mouth Larynx Pharynx
number of cases 2222 2648 1865
Risk of death relative to Relative 95% CI Relative 95% CI Relative 95% CI
Radiotherapy alone risk risk risk
Surgery alone 0.46 0.39–0.53 1.52 1.29–1.81 0.86 0.71–1.03
Radiotherapy & surgery 0.64 0.55–0.74 1.15 1.00–1.33 0.66 0.57–0.76
combined (<3 months apart)
Radiotherapy & surgery in 0.80 0.69–0.92 1.32 1.12–1.58 0.80 0.68–0.95
sequence (>3+ months apart)
Risk of death relative to
S&R in combination
Radiotherapy & surgery in 1.25 1.04–1.49 1.15 0.94–1.41 1.19 1.07–1.31
sequence (>3+ months apart)survival for pharyngeal cancers with no significant differences
between surgery and radiotherapy alone (Table 5).
Combined surgery and radiotherapy (within 3 months) was
associated with significantly better survival independent of tumour
and demographic factors for oral and pharyngeal cancers
compared with surgery and radiotherapy treatment in sequence
(more than 3 months apart, Table 5). All the survival differences
were most pronounced when prognosis was good (data not
shown). The differences in survival demonstrated were similar for
both crude and cause specific survival.
DISCUSSION
This is the first population-based large case series of UAT cancer
treatment in the UK. Although the study is limited by the unifor-
mity and completeness of the data it provides useful information
on treatment. The treatments given differ from those currently
recommended. This may be because the evidence for some recom-
mendations such as the benefits of post- rather than preoperative
radiotherapy was published in 1991 (Tupchong, 1991), after the
majority of the patients in this study were treated. This study
provides baseline information on treatment patterns. A future
population-based analysis of the UAT cancer treatment could audit
the effectiveness of the current guidelines. Both improved compar-
ability of treatment information between cancer registries and the
implementation of a national audit dataset for UAT cancers would
facilitate any future studies in this area.
The study highlights treatment differences by geographical area
and patient age and gender. Stell (1990) found that much of the
difference in survival by age group was accounted for by the
proportion not treated.
This was a retrospective observational study and because of this
the results of the survival analysis are less conclusive than a
prospective randomized controlled trial. Differences in recording
of treatment details between registries, the lack of TNM staging
and the incompleteness of the data limited the analysis. Although
the registry stage 1 is broadly equivalent to T1 and T2 this may
not have been so for a minority of cases. The details of surgical
procedures or radiotherapy doses are not available and so compar-
isons between different surgical or radiotherapy techniques are not
possible. For example, some of the people receiving both surgery
and radiotherapy may have had radiotherapy to the primary lesion
and a surgical neck dissection, or vice versa, rather than true
combined therapy to the primary tumour. Survival is only one
outcome among many and no information is available on function
or quality of life. As there are relatively few randomized controlled
trials in this area this study does provide some information on a
large population group and raises questions as to the effect of
different treatments on survival.
Survival was associated with the content of treatment. There are
many possible reasons for this. Potential biases include the propor-
tion of missing data, data accuracy and selection biases in treat-
ments. Although tumour site, extent of spread, tumour grade and
patient age and deprivation were taken into account in the model
there may have been clinical differences between treatment groups
that were not accounted for in the model. In order to find out if the
treatments cause the differences in survival greater involvement in
prospective large randomized trials or multi-centre audits would
be needed.
Oral cancer patients who had surgery had better survival than
patients who had combination treatment or radiotherapy. Although
surgery was associated with better survival for small oral cancers
(level 1, within organ of origin), either surgery or radiotherapy is
recommended for small oral cancers and only 33% of patients with
small oral cancers had surgery whilst 38% had radiotherapy. This
contrasts with the situation for advanced oral cancers where
combination therapy is of proven benefit (Mendenhall et al, 1988;
Weber et al, 1990). Nisi (1998) found that patients with advanced
tongue cancer treated by combination treatment had better local
control but no better survival than patients treated by surgery
alone. As patients who have combination treatment for oral cancer
have been shown to have worse quality of life than patients having
surgery alone (Finlay, 1984; Rathmell, 1991) the rationale for
combination treatment for T1 and T2 tumours may need to be
examined.
The better survival for patients with cancer of the larynx treated
by radiotherapy supports the findings of other studies (Vermund,
1990) and is in line with current recommendations (Table 1).
Combined treatment was associated with the best survival for
pharyngeal cancers as is recommended for T3 and T4 cancers.
The timing of treatments was associated with survival. Oral
cancer patients who had combined surgery and radiotherapy
(within 3 months) had better survival than those who had both
surgery and radiotherapy in sequence (3 months or more apart).
There are several possible explanations for this survival difference.
The delays may occur in patients who are physically unable to
undergo combination treatments due to their general condition; the
subsequent treatment may be for a recurrence; the treatment may
be palliative and episodic; or delays in treatment may allow
tumour repopulation and decrease survival as has been found in
other studies of UAT cancers (Amdur et al, 1989; Skaladowski
et al, 1994; Duncan et al, 1996; Wang et al, 1996). Appropriate
timing of treatments may improve survival of patients with UAT
cancers.
This study does not provide conclusive evidence that treatment
modality affects survival from cancers of the mouth, pharynx or
larynx. It does raise a number of questions. How well are treatment
protocols being followed? Does surgery produce better results than
radiotherapy for T1 and T2 tumours of the mouth in terms of
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Figure 1 Survival of patients with mouth cancers (C01–C06) confined to
organ of origin by treatmentsurvival, function and quality of life once detailed clinical factors
have been accounted for? Are there avoidable delays between
different modalities in combination therapy that affect survival?
The answers to these questions need to be investigated through
large randomized controlled trials and service audits that include
functional and quality of life components and systematic reviews
of randomized controlled trials.
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